Molecules and Cells

Korean Society for Molecular and Cellular Biology (한국분자세포생물학회)
권호 표지
DOI QR코드

DOI QR Code

Structural Identification of Modified Amino Acids on the Interface between EPO and Its Receptor from EPO BRP, Human Recombinant Erythropoietin by LC/MS Analysis

  • Song, Kwang-Eun (Department of Stereoscopic Media, Korean German Institute of Technology) ;
  • Byeon, Jaehee (Department of Stereoscopic Media, Korean German Institute of Technology) ;
  • Moon, Dae-Bong (BIOnSYSTEMS, Inc., R&D Center) ;
  • Kim, Hyong-Ha (Center for Bioanalysis, Korea Research Institute of Standards and Science) ;
  • Choi, Yoo-Joo (Department of Newmedia, Korean German Institute of Technology) ;
  • Suh, Jung-Keun (Department of Newmedia, Korean German Institute of Technology)
  • Received : 2014.07.28
  • Accepted : 2014.09.04
  • Published : 2014.11.30
Download PDF
⟨ Previous Next ⟩

Abstract

Protein modifications of recombinant pharmaceuticals have been observed both in vitro and in vivo. These modifications may result in lower efficacy, as well as bioavailability changes and antigenicity among the protein pharmaceuticals. Therefore, the contents of modification should be monitored for the quality and efficacy of protein pharmaceuticals. The interface of EPO and its receptor was visualized, and potential amino acids interacting on the interface were also listed. Two different types of modifications on the interface were identified in the preparation of rHu-EPO BRP. A UPLC/Q-TOF MS method was used to evaluate the modification at those variants. The modification of the oxidized variant was localized on the Met54 and the deamidated variants were localized on the Asn47 and Asn147. The extent of oxidation at Met54 was 3.0% and those of deamidation at Asn47 and Asn147 were 2.9% and 4.8%, respectively.

Keywords

References

  1. Brines, M., Patel, N.S., Villa, P., Brines, C., Mennini, T., De Paola, M., Erbayraktar, Z., Erbayraktar, S., Sepodes, B., Thiemermann, C., et al. (2008). Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc. Natl. Acad. Sci. USA 105, 10925-10930. https://doi.org/10.1073/pnas.0805594105
  2. Brinks, V., Hawe, A., Basmeleh, A.H., Joachin-Rodriguez, L., Haseberg, R., Somsen, G.W., Jiskoot, W., and Schellekens, H. (2011). Quality of original and biosimilar epoetin products. Pharm. Res. 28, 386-393. https://doi.org/10.1007/s11095-010-0288-2
  3. Chang, S.H., Kim, H.J., and Kim, C.W. (2013). Analysis of the structure and stability of erythropoietin by pH and temperature changes using various LC/MS. Bull. Korean Chem. Soc. 34, 2663-2670. https://doi.org/10.5012/bkcs.2013.34.9.2663
  4. Cheetham, J.C., Smith, D.M., Aoki, K.H., Stevenson, J.L., Hoeffel, T.J., Syed, R.S., Egrie, J., and Harvey, T.S. (1998). NMR structure of human erythropoietin and a comparison with its receptor bound conformation. Nat. Struct. Biol. 5, 861-866. https://doi.org/10.1038/2302
  5. Davis, J.M., Arakawa, T., Strickland, T.W., and Yphanitis, D.A. (1987). Characterization of recombinant human erythropoietin produced in Chinese hamster ovary cells. Biochemistry 26, 2633-2638. https://doi.org/10.1021/bi00383a034
  6. Delorme, E., Lorenzini, T., Giffin, J., Martin, F., Jacobsen, F., Boone, T., and Elliott, S. (1992). Role of glycosylation on the secretion and biological activity of erythropoietin. Biochemistry 31, 9871-9876. https://doi.org/10.1021/bi00156a003
  7. Elliott, S., Lorenzini, T., Chang, D., Barzilay, J., and Delorme, E. (1997). Mapping of the active site of recombinant human erythropoietin. Blood 89, 493-502.
  8. Eschbach, J.W., Abdulhadi, M.H., Browne, J.K., Delano, B.G., Downing, M.R., Egrie, J.C., Evans, R.W., Friedman, E.A., Graber, S.E., Haley, N.R., et al. (1989). Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann. Intern. Med. 111, 992-1000. https://doi.org/10.7326/0003-4819-111-12-992
  9. Gan, Y., Xing, J., Jing, Z., Stetler, R.A., Zhang, F., Luo, Y., Ji, X., Gao, Y., and Cao, G. (2012). Mutant erythropoietin without erythropoietic activity is neuroprotective against ischemic brain injury. Stroke 43, 3071-3077. https://doi.org/10.1161/STROKEAHA.112.663120
  10. Greer, F., Reason, A., and Rogers, M. (2002). Post-translational modifications of biopharmaceuticals-a challenge for analytical characterisation. Eur. Biopharm. Rev. 106-111.
  11. Lodish, H.F., Hilton, D.J., Klingmuller, U., Watowich, S.S., and Wu, H. (1995). The erythropoietin receptor: biogenesis, dimerization, and intracellular signal transduction. Cold Spring Harb. Symp. Quant. Biol. 60, 93-104.
  12. Syed, R.S., Reid, S.W., Li, C., Cheetham, J.C., Aoki, K.H., Liu, B., Zhan, H., Osslund, T.D., Chirino, A.J., Zhang, J., et al. (1998). Efficiency of signaling through cytokine receptors depends critically on receptor orientation. Nature 395, 511-516. https://doi.org/10.1038/26773
  13. Toyoda, T., Itai, T., Arakawa, T., Aoki, K.H., and Yamaguchi, H. (2000). Stabilization of human recombinant erythropoietin through interactions with the highly branched N-glycans. J. Biochem. 128, 731-737. https://doi.org/10.1093/oxfordjournals.jbchem.a022809
  14. Walsh, G. (2010). Post-translational modifications of protein biopharmaceuticals. Drug Discov. Today 15, 773-780. https://doi.org/10.1016/j.drudis.2010.06.009
  15. Winearls, C.G., Oliver, D.O., Pippard, M.J., Reid, C., Downing, M.R., and Cotes, P.M. (1986). Effect of human etythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 328, 1175-1178. https://doi.org/10.1016/S0140-6736(86)92192-6

Cited by

  1. Structural Identification of a Non-Glycosylated Variant at Ser126 for O-Glycosylation Site from EPO BRP, Human Recombinant Erythropoietin by LC/MS Analysis vol.38, pp.6, 2015, https://doi.org/10.14348/molcells.2015.2256
  2. Targeting EPO and EPO receptor pathways in anemia and dysregulated erythropoiesis vol.20, pp.3, 2016, https://doi.org/10.1517/14728222.2016.1090975
  3. Assessment for quantification of biopharmaceutical protein using a microvolume spectrometer on microfluidic slides vol.11, pp.1, 2017, https://doi.org/10.1007/s13206-016-1104-9
  4. Comprehensive Characterization ofN‐Glycosylation in Darbepoetin Alfa vol.40, pp.10, 2014, https://doi.org/10.1002/bkcs.11856
  5. Multi-Attribute Monitoring of Complex Erythropoetin Beta Glycosylation by GluC Liquid Chromatography-Mass Spectrometry Peptide Mapping vol.92, pp.11, 2014, https://doi.org/10.1021/acs.analchem.0c00124
  6. Cysteine Aminoethylation Enables the Site-Specific Glycosylation Analysis of Recombinant Human Erythropoietin using Trypsin vol.92, pp.14, 2014, https://doi.org/10.1021/acs.analchem.0c01794
  7. Anion exchange chromatography – Mass spectrometry for monitoring multiple quality attributes of erythropoietin biopharmaceuticals vol.1143, pp.None, 2014, https://doi.org/10.1016/j.aca.2020.11.027